AbbVie announces new data from its ADC platform

AbbVie announced that new data from its innovative antibody-drug conjugate, ADC, platform will be showcased at the upcoming European Society for Medical Oncology, ESMO, Congress 2024. Presentations include data on mirvetuximab soravtansine and c-Met targeting ADCs, telisotuzumab vedotin and telisotuzumab adizutecan, ABBV-400. AbbVie’s ADCs are designed to target protein biomarkers such as folate receptor-alpha and c-Met which are over expressed across various tumor types and are associated with poor prognoses.1-9 The ADCs are designed to deliver potent cancer cell-death inducing agents called ‘payloads’ specifically to the tumor, by utilizing these biomarkers as targets. Data from the primary analysis of the Phase 2 PICCOLO trial evaluating investigational mirvetuximab soravtansine monotherapy in heavily pre-treated patients with FRalpha positive, platinum-sensitive ovarian cancer showed that the trial met its primary endpoint with an objective response rate of 51.9%, including 6 complete and 35 partial responses. Among the 79 enrolled patients, 81% had prior poly polymerase inhibitors treatment; 74.7% of whom progressed while on PARPi. The median duration of response, a key secondary endpoint, was 8.3 months and median progression-free survival, an additional secondary endpoint, was 6.9 months.